Project Grant R21HL175170
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$131K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Vitalant (GKT4L2JZJ622)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), will fund a collaborative research program to investigate fundamental questions surrounding anti-ABO(H) antibodies and their target antigens on red blood cells. The $5,187,690 award, with a performance period from August 1, 2024 to July 31, 2029, will support three distinct research projects and complementary core facilities led by a multidisciplinary team of...
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) awarded a $1,123,357 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Childrens Hospital Medical Center in Cincinnati, Ohio. The funding supports a 7-year research program to investigate the specialized microenvironments within bone marrow that regulate blood cell production and response to inflammation. The research aims to define the spatial organization of the bone...
This $391,250.00 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of fibrinogen as a mediator of COVID-19-associated coagulopathy. The project aims to define the impact of therapeutic plasma exchange on blood rheology and vascular integrity in COVID-19 patients, as well as the effects of a variant fibrinogen isoform called Gc fibrinogen on red blood cell...
This $10,847,672 Project Grant awarded by the National Institute on Aging (part of the National Institutes of Health) under the Aging Research federal grant program (CFDA 93.866) aims to elucidate the mechanisms underlying cerebral amyloid angiopathy (CAA) and its relationship to Alzheimer's disease pathology. The research will leverage human postmortem brain samples, single-cell genomic profiling, and animal models to investigate how microglia regulate the balance between vascular CAA and...
This Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), is funding research to develop hemostatic red blood cells (T-RBCs) for the treatment of acute non-compressible hemorrhage. The $234,000 award, active from March 1, 2025 to February 28, 2027, will support the synthesis and in vitro/in vivo testing of these T-RBCs, which are engineered to adhere to collagen and fibrin clots to help stop...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $802,301 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Weill Medical College of Cornell University. The grant, running from June 10, 2025 to April 30, 2029, aims to investigate the mechanisms by which mutated blood stem cells reorganize the local bone marrow niche environment to promote their own expansion, a key driver of clonal hematopoiesis, a condition that increases risk for...
This federal Project Grant award for $445,708.00, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to define the role of platelet ABO(H) blood group antigens in hemostasis and thrombosis. The key objectives are to: 1) Determine the impact of ABO(H) glycans on platelet binding to von Willebrand factor (vWF), and 2) Identify the platelet glycoproteins that carry ABO(H) antigens using a click...
This $1,276,908 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports advanced molecular and translational research on the mechanisms of disease in von Willebrand disease (VWD) and sickle cell disease (SCD). The grant recipient, Bloodworks (doing business as Puget Sound Blood Center and Program), will utilize a variety of in vitro and in vivo approaches to investigate the impacts of von...
This $718,854 federal Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to Versiti Wisconsin, Inc., a non-profit blood center and research organization. The award supports research to elucidate the cellular mechanisms governing the non-conventional signaling function of the α5β1 integrin in the formation of tunneling nanotubes (TNTs) and inflammation in blood and endothelial cells. The...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded a $568,264 Project Grant (R41HL178144) to SAFI Biotherapeutics Inc. The goal of this Phase I STTR project is to develop a cost-efficient and scalable bioprocess for manufacturing designer red blood cells (RBCs) derived from induced pluripotent stem cells (iPSCs). These designer RBCs will be used as reagents to identify antibodies in patients requiring...